

Anatara Animal Health Update

MELBOURNE, 10th August 2020: Anatara Lifesciences Ltd (ASX:ANR) is pleased to provide an update on initiation of challenge study in poultry with the recently developed bromelain-based formulation (ANR-pf).

Anatara recently advised that it was finalising discussions with third parties to progress challenge trials of Anatara's animal health assets to address barriers to partnering.

Anatara has entered into an agreement with the University of New England's Poultry Hub Australia to undertake the study "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges". This study is anticipated to be completed by 31 January 2021.

This project is supported by Poultry Hub Australia (formerly the Poultry CRC), through funding from AgriFutures Australia as part of its AgriFutures Chicken Meat Program.

Necrotic Enteritis (NE) is the most common and financially devastating bacterial disease in modern broiler flocks.¹

This economically significant disease, caused by the bacterium *Clostridium perfringens*, causes lesions in the chicken's intestine and can lead to flock mortality of 1% per day (clinical NE). The true economic impact of NE though is felt not from those birds that die from infection, but those who suffer from disease but survive subclinical NE. The true costs of NE could come close to US\$6 billion.²

CEO Steve Lydeamore commented, "Anatara is pleased to have engaged with Poultry Hub Australia to conduct trials at the University of New England. Our objectives are aligned – to help Australia achieve sustainable, ethical poultry production."

¹ poultryhub.org/health/disease/types-of-disease/necrotic-enteritis/; accessed 10 August 2020

² poultryworld.net/Meat/Articles/2015/10/The-true-cost-of-necrotic-enteritis-2699819W/; Oct 9, 2015; accessed 10 August 2020



For more information please contact:

General inquiries	
Steven Lydeamore CEO, Anataro Lifesciences Ltd +61 (0) 438 027 172 slydeamore@anataro.com	Sue MacLeman Chair, Anataro Lifesciences Ltd +61 (0) 437 211 200 smacleman@anataro.com

About Anataro Lifesciences Ltd

Anataro Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based products for gastrointestinal health where there is significant unmet need. Anataro is a life sciences company with expertise in developing products for animal and human health. Anataro is focused on building a pipeline of human gastrointestinal health products. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.

Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anataro Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anataro Lifesciences Limited**Registered Office**

Level 3, 62 Lygon Street, Carlton South, VIC, 3053, Australia

Administration and R&D

343 Royal Parade, Parkville, Melbourne, VIC 3052, Australia

Email info@anataro.com | Website anatarolifesciences.com

